Dr. Hodak’s clinical research focuses on the use of molecular genetic tools to improve diagnostic yield of thyroid nodule fine-needle aspiration biopsies. These novel techniques allow better risk stratification of thyroid cancer patients and identify those thyroid nodules most likely to be benign so they may be followed conservatively without surgery. These important molecular tools spare many patients from unnecessary thyroid surgery, and minimize associated human and economic costs. Dr. Hodak has co-authored numerous peer-reviewed articles in this field, performs hundreds of thyroid fine-needle biopsies annually, and has developed patient databases and tissue biorepositories required for successful translational research. Through his work, Dr. Hodak has become nationally recognized in the field of thyroid cancer and molecular diagnostics, serving on professional committees and speaking widely. He has been a past thyroid section chair for the Endocrine Society's Clinical Endocrinology Update Steering Committee and continues to serve on the American Thyroid Association Clinical Affairs Committee where he authored that group’s position statement regarding clinical use of molecular genetic testing for thyroid cancer diagnosis. He is a Best Doctor in New York and has been recognized annually as one of America’s Best Doctors for over a decade.